Completed PHASE2 INTERVENTIONAL 2-arm NCT00638456

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial

Sponsor: Meritage Pharma, Inc.

Interventions Budesonide plus Prevacid placebo plus Prevacid

Updated 7 times since 2017 Last updated: Jul 25, 2019 Started: Feb 29, 2008 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00638456, this PHASE2 trial focuses on Eosinophilic Esophagitis and remains completed. Sponsored by Meritage Pharma, Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Meritage Pharma, Inc.
Ranjan Dohil

Data source: University of California, San Diego

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Diego, United States